Frits van Coevorden

Frits van Coevorden

Auto-generated profile, based on publicly available information

Frits van Coevorden


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2013 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski
AGAlessandro Gronchi
Alessandro Gronchi
PHPeter Hohenberger
Peter Hohenberger
SBSylvie Bonvalot
Sylvie Bonvalot
PSPatrick Schöffski
Patrick Schöffski
FCFrits van Coevorden
Frits van Coevorden

15 April 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CRChandrajit Raut
Chandrajit Raut
DCDario Callegaro
Dario Callegaro
RMRosalba Miceli
Rosalba Miceli
FBFrancesco Barretta
Francesco Barretta
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski
AGAlessandro Gronchi
Alessandro Gronchi
Purpose: The role of surgery for first relapse locally recurrent retroperitoneal sarcoma (RPS-LR1) is uncertain. We report outcomes of the largest RPS-LR1 series and propose a new prognostic nomogram.Experimental Design: Patients with consecutive RPS-LR1 without distant metastases who underwent resection at 22 centers (2002–2011) were included. Endpoints were disease-free and overall survival (DFS, OS) and crude-cumulative-incidence (CCI) of local/distant recurrence from second surgery. Nomograms predicting DFS and OS from second surgery were developed and validated (calibration plots); discrimination was assessed (Harrell C index).Results: Of 684 patients identified, full prognostic variable data were available for 602. Initial surgery for primary RPS was performed at our institutions in 188 patients (31%) and elsewhere in 414 (69%). At a median follow-up of 119 months [Interquartile range (IQR), 80–169] from initial surgery and 75 months (IQR 50–105) from second surgery, 6-year DFS and OS were 19.2% [95% confidence interval (CI), 16.0–23.0%] and 54.1% (95% CI, 49.8–58.8%), respectively. Recurrence patterns and survival probability were histology-specific, with liposarcoma subtypes having the highest 6-year CCI of second local recurrence (LR, 60.2%–70.9%) and leiomyosarcoma (LMS) having higher 6-year CCI of distant metastasis (DM, 36.3%). Nomograms included age at second surgery, multifocality, grade, completeness of second surgery, histology, chemotherapy/radiotherapy at first surgery, and number of organs resected at first surgery. OS and DFS nomograms showed good calibration and discriminative ability (C index 0.70 and 0.67, respectively).Conclusions: We developed nomograms to predict DFS and OS for patients undergoing RPS-LR1 resection. Nomograms provide individualized, disease-relevant estimations of survival for RPS-LR1 patients and assist in clinical decisions.

27 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KHKimberley Heinhuis
Kimberley Heinhuis
SVSjors G. J. G. In ’T Veld
Sjors G. J. G. In ’T Veld
GDGovert Dwarshuis
Govert Dwarshuis
DBDaan van Den Broek
Daan van Den Broek
NSNik Sol
Nik Sol
NSNeeltje Steeghs
Neeltje Steeghs
Sarcoma is a heterogeneous group of rare malignancies arising from mesenchymal tissues. Recurrence rates are high and methods for early detection by blood-based biomarkers do not exist. Hence, development of blood-based liquid biopsies as disease recurrence monitoring biomarkers would be an important step forward. Recently, it has been shown that tumor-educated platelets (TEPs) harbor specific spliced ribonucleic acid(RNA)-profiles. These RNA-repertoires are potentially applicable for cancer diagnostics. We aim to evaluate the potential of TEPs for blood-based diagnostics of sarcoma patients. Fifty-seven sarcoma patients (active disease), 38 former sarcoma patients (cancer free for ≥3 years) and 65 healthy donors were included. RNA was isolated from platelets and sequenced. Quantified read counts were processed with self-learning particle-swarm optimization-enhanced thromboSeq analysis and subjected to analysis of variance (ANOVA) statistics. Highly correlating spliced platelet messenger RNAs (mRNAs) of sarcoma patients were compared to controls (former sarcoma + healthy donors) to identify a quantitative sarcoma-specific signature measure, the TEP-score. ANOVA analysis identified distinctive platelet RNA expression patterns of 2647 genes (false discovery rate <0.05) in sarcoma patients as compared to controls. The self-learning algorithm reached a diagnostic accuracy of 87% (validation set only; n = 53 samples, area under the curve (AUC): 0.93, 95% confidence interval (CI): 0.86–1). Our data indicates that TEP RNA-based liquid biopsies may enable for sarcoma diagnostics.

1 April 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
JLJules Lansu
Jules Lansu
JGJan Groenewegen
Jan Groenewegen
FCFrits van Coevorden
Frits van Coevorden
WHWinan J. van Houdt
Winan J. van Houdt
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi
Rick HaasRick Haas
Rick Haas

1 January 2004 in Sarcoma
Verified
Journal Article
Open access
PDF file
CKClaudia M. G. Keyzer-Dekker
Claudia M. G. Keyzer-Dekker
RHRichard G. Houtkamp
Richard G. Houtkamp
JPJohannes L. Peterse
Johannes L. Peterse
FCFrits Van Coevorden
Frits Van Coevorden
Introduction. Adult pelvic soft tissue sarcomas are a rare group of heterogeneous malignancies. These sarcomas differ from extremity and trunk soft tissue sarcomas in presentation, characteristics and response to treatment.

26 August 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
DBDanique L.M. van Broekhoven
Danique L.M. van Broekhoven
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
TDThijs van Dalen
Thijs van Dalen
FCFrits van Coevorden
Frits van Coevorden
HBHan J. Bonenkamp
Han J. Bonenkamp
Cornelis VerhoefCornelis Verhoef
Cornelis Verhoef
The efficacy of the classical treatment modalities surgery and radiotherapy in the treatment of aggressive fibromatosis is presently disputed and there is a shift towards a more conservative approach. The aim of the present study is to objectify tumor growth in patients with extra-abdominal or abdominal wall aggressive fibromatosis, while adhering to a “watchful waiting” policy. Other objectives are to investigate quality of life and to identify factors associated with tumor growth, in particular the relation with the presence of a CTNNB1-gene mutation in the tumor. GRAFITI is a nationwide, multicenter, prospective registration trial. All patients with extra-abdominal or abdominal wall aggressive fibromatosis are eligible for inclusion in the study. Main exclusion criteria are: history of familiar adenomatous polyposis, severe pain, functional impairment, life/limb threating situations in case of progressive disease. Patients included in the study will be treated with a watchful waiting policy during a period of 5 years. Imaging studies with ultrasound and magnetic resonance imaging scan will be performed during follow-up to monitor possible growth: the first years every 3 months, the second year twice and the yearly. In addition patients will be asked to complete a quality of life questionnaire on specific follow-up moments. The primary endpoint is the rate of progression per year, defined by the Response Evaluation Criteria In Solid Tumors (RECIST). Secondary endpoints are quality of life and the rate of influence on tumor progression for several factors, such as CTNNB1-mutations, age and localization. This study will provide insight in tumor behavior, the effect on quality of life and clinicopathological factors predictive of tumor progression. The GRAFITI trial is registered in the Netherlands National Trial Register (NTR), number 4714 .